Please use this identifier to cite or link to this item:
|Title:||Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer - A single center randomized study|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.|
Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Kulak Burun ve Boğaz Hastalıkları Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.
Coşkun, H. Hakan
Turan, Ömer Faruk
Cisplatin plus vinorelbine
|Citation:||Kanat, Ö. vd. (2003). “Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer - A single center randomized study”. Medical Oncology, 20(3), 237-245.|
|Abstract:||Aim: In this study we determined the protective role of amifostine against the side effects of the combination of paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Chemo-naive patients with NSCLC were eligible. Thirty-eight patients were randomized to receive paclitaxel 175 mg/m(2) and carboplatin AUC = 6 with amifostine 9 10 mg/m(2) (group 13) or chemotherapy alone (group A). The occurrences of hematologic, neurologic, cardiologic toxicities, and ototoxicity were evaluated. Results: All patients completed the six scheduled cycles of therapy. A total of H 4 cycles of chemotherapy was given in both groups. Neutropenia grade 3-4 was observed in 11 cycles (9.6%) in group A and 19 cycles (16.6%) in group B (p = 0.16). Paresthesia grade 1 or 2 was observed in 18 of 19 patients of group A and in 8 of 19 patients of group B, following the sixth cycle of chemotherapy (p = 0.018). Two patients of group B and nine patients of group A suffered from sensory motor impairment grade 2 (p = 0.029). There was no clinical evidence in any patient for deterioration in cardiac function. Asymptomatic and transient sinus bradycardia or ventricular premature beats developed in four patients. None of the patients reported vertigo, tinnitus, or hearing loss. Conclusion: The addition of the amifostine to the combination of paclitaxel and carboplatin may prevent or reduce the incidence of neurotoxicity in the treatment of NSCLC. Amifostine does not appear to have a preventive role in neutropenia.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.